Corcept Therapeutics Incorporated
CORTNASDAQHealthcare● Active
$72.62
$-2.27(-3.03%)
Market Cap$7.8B
P/E Ratio—
52W High$91
52W Low$28.66
Corcept Therapeutics Incorporated (CORT) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CORT · as of 2026-06-08
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.10B | $0.14B | $0.11B | $0.10B | $0.11B |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.08B | $0.06B | $0.05B | $0.04B | $0.04B |
| Change in Working Capital | ($0.03B) | $0.05B | $0.01B | $0.01B | ($0.00B) |
| Net Cash from Operations | $0.14B | $0.20B | $0.13B | $0.12B | $0.17B |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.32B) | ($0.59B) | ($0.33B) | ($0.36B) | ($0.31B) |
| Sales of Investments | $0.39B | $0.41B | $0.42B | $0.24B | $0.45B |
| Net Cash from Investing | $0.07B | ($0.18B) | $0.09B | ($0.11B) | $0.14B |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.25B) | ($0.02B) | ($0.15B) | $0.00B | ($0.30B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | ($0.22B) | ($0.03B) | ($0.15B) | ($0.02B) | ($0.30B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.14B | $0.20B | $0.13B | $0.12B | $0.17B |
| FCF Margin %(computed) | 18.62% | 29.02% | 26.31% | 29.84% | 45.75% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Corcept Therapeutics Incorporated data
About Corcept Therapeutics Incorporated (CORT) Cash Flow Statement
Corcept Therapeutics Incorporated generated operating cash flow of $0.14B and free cash flow of $0.14B for 2025 — a FCF margin of 18.62%. Capital expenditure was ($0.00B).
Frequently asked questions
CORT · 4 questionsCorcept Therapeutics Incorporated generated free cash flow of $0.14B for 2025, down 27.6% year-over-year.
CORT free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08